Orthogon Therapeutics

About Orthogon Therapeutics

Orthogon Therapeutics is a biotechnology company focused on bridging frontier research with formal drug development. Their mission is to provide groundbreaking therapeutic options for common viral infections, particularly in transplant patients, through innovative drug discovery platforms.

Products & Services

Anti-Polyomavirus Drugs:A portfolio of orally administrable drugs targeting polyomaviruses (BK, JC, Merkel cell, and others) through novel mechanisms of action, focusing on unconventional drug targets like VP1 capsid, Large T-antigen, and virus-specific host targets.

BK Virus Treatment:Pioneering the first treatment for BK virus infections, specifically aimed at transplant patients, with a pipeline of promising antiviral drugs.

Specialties

Drug Discovery Platform Polyomavirus Treatments Antiviral Drug Development Machine Learning and Artificial Intelligence in Drug Development 3D Atomic Mapping of Drug-Protein Binding Target-Enriched Compound Libraries 3D atomic coordinate mapping of drug-protein binding Privileged and target-enriched compound libraries Atomic-level kinetics and thermodynamics analysis ML/AI-driven drug discovery

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Follow-on T: - FT: Follow-on	A: 11000000 MR: - FA: $11 million FAN: 11000000	D: 2026-04-17 FD: 2026-04-17	-
2	RT: Oversubscribed Financing T: - FT: Oversubscribed Financing	A: 5200000 MR: - FA: $5.2M FAN: 5200000	D: 2024-12-10 FD: 2024-12-10	-

Follow-on Latest

2026-04-17

$11.0M

Oversubscribed Financing 2024-12-10

$5.2M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

No team data available

Team information is not yet available for this company

Recent News